Results 21 to 30 of about 387,352 (250)
Possible role of
European Journal of Haematology, 2023 AbstractRituximab and prednisone are commonly used treatments for autoimmune hemolytic anemia (AIHA), where the body's immune system attacks and destroys its red blood cells. However, some AIHA patients may become refractory to rituximab treatment, and this can result in continued hemolysis and persistent anemia, making it challenging for affected ...
Naveen Premnath +3 more
openaire +2 more sources
Pharmaceuticals, 2023 Targeted therapies represent major advancements in the treatment of chronic skin conditions such as psoriasis. While previous studies have shown an increased risk of melanoma and non-melanoma skin cancer (NMSC) in patients receiving TNF-α inhibitors, the
Marta Krzysztofik +7 more
doaj +1 more source
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
Frontiers in Pharmacology, 2019 Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease.
Lazaros I. Sakkas +2 more
doaj +1 more source
How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis
Journal of Dermatological Treatment, 2018 Sir,With the advent of novel biologic agents for psoriasis, such as IL-17 inhibitors and IL-23 inhibitors, the treatment options available for psoriasis have increased considerably.
Mina, Amin, Erica B, Lee, Jashin J, Wu
openaire +2 more sources
Annals of MedicineBackground Interleukin (IL)-23 inhibitors—including IL-23p19 inhibitors (guselkumab, mirikizumab, risankizumab) and the IL-12/23p40 inhibitor ustekinumab—are emerging treatments for Crohn’s disease (CD), but comparative data among them remain limited ...
Motoki Kaneko, Atsushi Sakuraba
doaj +1 more source
IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
Научно-практическая ревматология, 2019 Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing ...
E. L. Nasonov +3 more
doaj +1 more source
International Journal of Inflammation, 2012 This review identifies possible pharmacological targets for inflammatory bowel disease (IBD) within the IL-23/IL-17 axis. Specifically, there are several targets within the IL-23/IL-17 pathways for potential pharmacological intervention with antibodies ...
Leo R. Fitzpatrick
doaj +1 more source
SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐23 inhibitor [PDF]
Journal of the European Academy of Dermatology and Venereology, 2020 Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID‐19 in this ...
Messina, F., Piaserico, S.
openaire +1 more source
Научно-практическая ревматология, 2022 Among the pathophysiological mechanisms of immune-mediated inflammatory diseases (IMIDs), specific attention has been paid to the abnormal activation of Th17 type immune response related to the dysregulated synthesis of cytokines forming the interleukin (
E. L. Nasonov +3 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source